Lipigon Pharmaceuticals AB ("Lipigon") is pleased to announce that new research findings, published in the European Heart Journal Open, further enhance the understanding of ANGPTL4 as a target protein for treating cardiovascular disease and type 2 diabetes. The research illuminates its therapeutic role, supporting the development prospects for Lipigon's drug candidate, Lipisense^®, to potentially address these conditions in the future.

Lipigon's research team, led by Fredrik Landfors, conducted the study titled 'Drug-target Mendelian randomization analysis supports lowering plasma ANGPTL3, ANGPTL4, and APOC3 levels as strategies for reducing cardiovascular disease risk'. The study has been published in the European Heart Journal Open, a peer-reviewed journal within the European Society of Cardiology.

The study utilized Mendelian randomization and meta-analyses of genetic association studies to examine the effects of the proteins ANGPTL3, ANGPTL4, and APOC3, which play a central role in the body's fat metabolism. By analyzing genetic data from large-scale genome-wide association studies, including UK Biobank, the researchers demonstrated that strategic manipulation of these proteins can reduce triglyceride levels, thereby decreasing the risk of cardiovascular disease and type 2 diabetes. Specifically, ANGPTL4 plays a crucial role in this process, which could potentially lead to improved outcomes for patients with these conditions.

Genetic Validation as a Key to Success
Genetic validation is a fundamental component in developing new pharmaceuticals, utilizing scientific methods to verify that specific genetic variants or proteins are directly involved in disease mechanisms. This process is essential for determining the efficacy and relevance of potential drug targets.

Fredrik Landfors, Clinical Scientist at Lipigon, comments: "This publication validates the scientific rigor of our methodology and underscores the significance of ANGPTL4 as a promising therapeutic target for both cardiovascular disease and type 2 diabetes. By genetically validating ANGPTL4, the target protein in our drug candidate Lipisense^®, prospects for Lipisense^® to successfully progress through all clinical trial phases are enhanced, as is our ability to predict the drug's efficacy and safety.'"

Read the full study here: Drug-target Mendelian randomization analysis supports lowering plasma ANGPTL3, ANGPTL4, and APOC3 levels as strategies for reducing cardiovascular disease risk.

For more information, please contact:
Stefan K. Nilsson, CEO, Lipigon
Email: stefan@lipigon.se
Phone: +46 705 78 17 68

About Lipigon

Lipigon Pharmaceuticals AB is a clinical-stage pharmaceutical company developing drugs with new, unique mechanisms of action (first-in-class) for diseases caused by disorders in the body's handling of fats. The company's operations are based on over 50 years of lipid research at Umeå University, Sweden. Lipigon initially focuses on orphan drugs and niche indications, but in the long term, the company has the possibility to target broader indications, such as diabetes and cardiovascular disease. Lipigon's pipeline includes three active projects: the RNA drug Lipisense^® targeting elevated triglycerides, with Phase II studies approved in February 2024; an RNA drug for treating lung damage; and a small molecule program for the treatment of dyslipidemia in collaboration with HitGen Inc. Read more at www.lipigon.se.

The company's share (LPGO) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.

Attached files